Paper - WANFANG MED ONLINE

You Position: Home > Paper

Systemic factors associated with treatment response in patients with diabetic macular edema

( views:147, downloads:18 )

Author:: No author available

Journal Title:: Chinese Journal of Ocular Fundus Diseases

Issue:: 3

DOI:: 10.3760/cma.j.cn511434-20200526-00244

Key Word:: 糖尿病视网膜病变;黄斑水肿;治疗;预后;综述;Diabetic retinopathy;Macular edema;Therapy;Prognosis;Review

Abstract： Diabetic macular edema (DME) is the main cause of vision loss and even blindness in patients with diabetic retinopathy. Intravitreal anti-vascular endothelial factor therapy has become the gold standard management of DME. However, not all eyes response optimally to common management of DME, which could be due to the differences of individual factors. Increasing age could be the predictive factors for poor outcome. The influence of glycemic control, hypertension, dyslipidemia, chronic kidney disease and relative factors on treatment response require further investigation. Identifying the systemic factors that influence the treatment response of DME can provide the evidence to predict the prognosis of DME, and improve the efficacy of clinical treatment.

Reference

[1]Diana V, Do,Xue, Wang,Satyanarayana S, Vedula,etc.Blood pressure control for diabetic retinopathy.[J].2015,1.
[2]Xuenan,Zhuang,Dan,Cao,Dawei,Yang,etc.Association of diabetic retinopathy and diabetic macular oedema with renal function in southern Chinese patients with type 2 diabetes mellitus: a single-centre observational study.[J].2019,9(9).
[3]Summanen PA,Williamson E,Mitchell P,etc.Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.[J].2007,370(9600).
[4]D S, Fong,F L, Ferris,M D, Davis,etc.Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group.[J].1999,127(2).
[5]Singh, Rishi P.,Habbu, Karishma,Ehlers, Justis P.,etc.The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema[J].2016,123(7).
[6]Lachin, John M..Effect of Intensive Diabetes Therapy on the Progression of Diabetic Retinopathy in Patients With Type 1 Diabetes: 18 Years of Follow-up in the DCCT/EDIC[J].2015,64(2).
[7]Gianni,Virgili.Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.[J].2018,10.
[8]Maguire, Maureen G.,Hopkins, Johns,Dhoot, Dilsher S.,etc.Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy An Exploratory Analysis of the Protocol T Randomized Clinical Trial[J].2019,137(4).
[9]Anca,Hermenean,Maria Consiglia,Trotta,Sami,Gharbia,etc.Changes in Retinal Structure and Ultrastructure in the Aged Mice Correlate With Differences in the Expression of Selected Retinal miRNAs.[J].2020,11.
[10]Bressler, Neil M.,Beaulieu, Wesley T.,Glassman, Adam R.,etc.Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment A Secondary Analysis of a Randomized Clinical Trial[J].2018,136(3).
[11]Takamura Yoshihiro,Matsumura Takehiro,Ohkoshi Kishiko,etc.Functional and anatomical changes in diabetic macular edema after hemodialysis initiation: One-year follow-up multicenter study[J].2020,10(1).
[12]Ramanuj.Samanta,Athul.Puthalath,Neeraj.Saraswat,etc.Rapidly reversing bilateral macular edema associated with fluid overload in a young type 1 diabetic[J].2019,67(7).
[13]Henry F, Edelhauser,Cheryl L, Rowe-Rendleman,Michael R, Robinson,etc.Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.[J].2010,51.
[14]Eman Saeed Al,Kahtani.Diabetic glomerulosclerosis can be the pathogenesis of refractory diabetic macular edema.[J].2015,9.
[15]Alastair David Bezzina,Francis Carbonaro.Factors Predicting Treatment Response in Anti-Vascular Endothelial Growth Factor Na?ve Diabetic Macular Edema Patients Treated with Intravitreal Bevacizumab[J].2019,35(10).
[16]Lavnish, Joshi,Asaf, Bar,Oren, Tomkins-Netzer,etc.Intravitreal bevacizumab injections for diabetic macular edema - predictors of response: a retrospective study.[J].2016,(Spec ).
[17]Barrett, Eugene J.,Liu, Zhenqi,Khamaisi, Mogher,etc.Diabetic Microvascular Disease: An Endocrine Society Scientific Statement[J].2017,102(12).
[18]Rishi P,Singh,Charles C,Wykoff,David M,Brown,etc.Outcomes of Diabetic Macular Edema Patients by Baseline Hemoglobin A1c: Analyses from VISTA and VIVID.[J].2019,1(5).
[19]Tan, Gavin S.,Cheung, Ning,Simo, Rafael,etc.Diabetic macular oedema[J].2017,5(2).
[20]Christina J,Flaxel,Ron A,Adelman,Steven T,Bailey,etc.Diabetic Retinopathy Preferred Practice Pattern®.[J].2020,127(1).
[21].Hemodialysis-induced alterations in macular thickness measured by optical coherence tomography in diabetic patients with end-stage renal disease[J].2012,227(2).
[22].Pretreatment clinical variables associated with the response to intravitreal bevacizumab (Avastin) injection in patients with persistent diabetic macular edema[J].2010,24(4).
[23]Ting, Daniel Shu Wei,Cheung, Gemmy Chui Ming,Wong, Tien Yin.Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review[J].2016,44(4).
[24]Do, D. V.,Shah, S. M.,Sung, J. U.,etc.Persistent diabetic macular edema is associated with elevated hemoglobin A1c[J].2005,139(4).
[25].Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration[J].2018.
[26]Lee Ryan,Wong Tien Y.,Sabanayagam Charumathi.Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss[J].2015,2(1).
[27]Yoon Young Hee,Boyer David S.,Maturi Raj K.,etc.Natural history of diabetic macular edema and factors predicting outcomes in sham-treated patients (MEAD study)[J].2019,257(12).
[28]Dhoot, Dilsher S.,Baker, Keith,Saroj, Namrata,etc.Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID.[J].2018,125(1).
[29]Wendy Meihua Wong,Caroline Chee,Mayuri Bhargava,etc.Systemic Factors Associated with Treatment Response in Diabetic Macular Edema[J].2020,2020.
[30]Das, Radha,Kerr, Rebecca,Chakravarthy, Usha,etc.Dyslipidemia and Diabetic Macular Edema A Systematic Review and Meta-Analysis[J].2015,122(9).
[31]Sophie, Raafay,Lu, Na,Campochiaro, Peter A..Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab[J].2015,122(7).
[32]E. Martín-Merino,J. Fortuny,E. Rivero-Ferrer,etc.Risk factors for diabetic macular oedema in type 2 diabetes: A case-control study in a United Kingdom primary care setting[J].2017,11(3).
[33].The Effect of Age on Aflibercept (Eylea) Response in Diabetic Macular Edema[J].2020,40(6).
[34].Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory.[J].2016.
[35]Chung Yoo-Ri,Park Sung Wook,Choi Shin-Young,etc.Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy[J].2017,16(1).